KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma

Summary

The study is to evaluate the efficacy of KL-A167 injection in subjects with recurrent/metastatic Nasopharyngeal Carcinoma, as measured by Overall Response Rate (ORR) per the Response Evaluation Criteria in Solid Tumors RECIST Version 1.1

Timeline

Start

2019-03-06

Primary completion

2021-07-13

Completion

2022-01-13

Publications

• Min Y, Liu X, Wei Z, Song G, Li Y, Gao K, Liu Z, Pei Y, Li H, Ge J, Qing Y, Wei Y, Peng X. Lung immune prognostic index is associated with clinical outcomes in recurrent or metastatic (R/M) nasopharyngeal carcinoma receiving immunotherapy: Results from the multicenter, single-arm, phase 2 study. Oral Oncol. 2024 Dec;159:107028. doi: 10.1016/j.oraloncology.2024.107028. Epub 2024 Sep 18.

Drugs

Indications